Related Experiment Videos

microRNA-22 can regulate expression of the long non-coding RNA MEG3 in acute myeloid leukemia

Hongxia Yao1, Pei Sun2, Mengling Duan1

  • 1Department of Hematology, Hainan General Hospital, Haikou, Hainan 570311, P.R. China.

Oncotarget
|October 15, 2017
PubMed
Abstract

Insights

Long non-coding RNA MEG3 is significantly decreased in acute myeloid leukemia (AML). This study investigated the molecular mechanisms behind this downregulation, crucial for understanding AML progression and developing new therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Regulation

Background:

  • Acute myeloid leukemia (AML) is a prevalent blood malignancy with a poor prognosis.
  • The molecular mechanisms underlying AML pathogenesis, including genetic and epigenetic alterations, remain incompletely understood.
  • Long non-coding RNA MEG3, a known tumor suppressor, is downregulated in AML, but the reasons for this are unclear.

Purpose of the Study:

  • To investigate the molecular mechanism of abnormal MEG3 expression in acute myeloid leukemia (AML).
  • To explore the role of MEG3 and TET2 in AML cell proliferation and their relationship with specific microRNAs.

Main Methods:

  • Real-time quantitative PCR (RT-qPCR) was used to detect the expression levels of MEG3, TET2, miR-22-3p, and miR-22-5p in AML.
  • Stable MEG3 and TET2 overexpression cell pools were established in K562 cells for functional studies.
  • Cell proliferation was assessed using MTT assays following gene manipulation.

Main Results:

  • Downregulation of MEG3 and TET2 was confirmed in AML cell lines via RT-qPCR.
  • Successful establishment of stable MEG3 and TET2 overexpressing K562 cell lines.
  • Overexpression of TET2 led to a significant increase in AML cell proliferation.

Conclusions:

  • MEG3 expression is significantly downregulated in AML cell lines.
  • Further research is needed to elucidate the precise molecular mechanisms driving AML.

Related Concept Videos